Inadequate vitamin D status in adolescents with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate injectable contraceptive: A pilot study

Journal of Pediatric and Adolescent Gynecology

Volumn 23, Issue 4, 2010, Pages 209-214

  Harel, Z ^a   Wolter, K ^b   Gold, M A ^c   Cromer, B ^d   Bruner, A ^e   Stager, M ^d   Bachrach, L ^f   Hertweck, P ^g   Nelson, A ^h   Nelson, D ⁱ   Coupey, S ^j   Johnson, C C ^k   Burkman, R ^l   Bone, H ^m  

^a HASBRO CHILDREN'S HOSPITAL   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d METROHEALTH MEDICAL CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF LOUISVILLE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^k HENRY FORD HEALTH SYSTEM   (United States)

^l BAYSTATE MEDICAL CENTER   (United States)

^m Michigan Bone and Mineral Clinic   (United States)

more..

Author keywords

Adolescents; Bone mineral density; Female; Med roxyprogesterone acetate (DMPA, Depo Provera); Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; MEDROXYPROGESTERONE ACETATE; OSTEOCALCIN; PARATHYROID HORMONE; VITAMIN D; CONTRACEPTIVE AGENT; DRUG IMPLANT;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BODY MASS; BONE DENSITY; CAUCASIAN; CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ETHNICITY; FEMALE; FEMUR NECK; FOLLOW UP; HIP; HISPANIC; HUMAN; LUMBAR SPINE; MULTICENTER STUDY; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; URINE LEVEL; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; BLOOD; BONE DISEASES, METABOLIC; COMPLICATION; DRUG EFFECTS; DRUG IMPLANT; PILOT STUDY;

ADOLESCENT; BONE DENSITY; BONE DISEASES, METABOLIC; CONTRACEPTIVE AGENTS, FEMALE; DRUG IMPLANTS; FEMALE; HUMANS; MEDROXYPROGESTERONE ACETATE; PARATHYROID HORMONE; PILOT PROJECTS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 77954027251     PISSN: 10833188     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpag.2009.11.004     Document Type: Article

References (36)

1. Harel Z., Cromer B. The use of long-acting contraceptives in adolescents. Pediatr Clin North Am 1999, 46:719.
2. Trussell J. Contraceptive efficacy. Contraceptive Technology 2007, Ardent Media, New York. 19th ed. R.A. Hatcher, J. Trussell, A.L. Nelson (Eds.).
3. Piccinino L.J., Mosher W.D. Trends in contraceptive use in the United States: 1982-1995. Fam Plann Perspect 1998, 30:4.
4. US Bureau of the Census: United States Census 2000 Summary File 1 2000, US Dept of Commerce, Economics and Statistics Administration, Washington, DC.
5. Cundy T., Evans M., Roberts H., et al. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ 1991, 303:13.
6. Gbolade B., Ellis S., Murby B., et al. Bone density in long-term users of depot medroxyprogesterone acetate. Br J Obstet Gynaecol 1998, 105:790.
7. Cundy T., Cornish J., Roberts H., et al. Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol 1998, 92:569.
8. Paiva L.C., Pinto-Neto A.M., Faundes A. Bone density amongst long-term users of medroxyprogesterone acetate as a contraceptive. Contraception 1998, 58:351.
9. Scholes D., Lacroix A.Z., Ott S.M., et al. Bone mineral density in women using depot medroxyprogesterone for contraception. Obstet Gynecol 1999, 93:233.
10. Tang O.S., Tang G., Yip P., et al. Long-term depot medroxyprogesterone acetate and bone mineral density. Contraception 1999, 59:25.
11. Cromer B.A., Blair J.M., Mahan J.D., et al. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr 1996, 129:671.
12. Busen N.H., Britt R.B., Rianon N. Bone mineral density in a cohort of adolescent women using depot medroxprogesterone acetate for one to two years. J Adolesc Health 2003, 32:257.
13. Lara-Torre E., Edwards C.P., Perlman S., et al. Bone mineral density in adolescent females using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol 2004, 17:17.
14. Cromer B.A., Stager M., Bonny A., et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health 2004, 35:434.
15. Accessed January 27, 2005. http://www.fda.gov/medwatch/SAFETY/2004/DepoProvera_Label.pdf.
16. Cromer A.C., Scholes D., Berenson A., et al. Depot medroxyprogesterone acetate and bone mineral density in adolescents-the black box warning: A position paper of the Society for Adolescent Medicine. J Adol Health 2006, 39:296.
17. Ott S.M., Scholes D., LaCroix A.Z., et al. Effects of contraceptive use on bone biochemical markers in young women. J Clin Endocrinol Metabol 2001, 86:179.
18. Rome E., Ziegler J., Secic M., et al. Bone biochemical markers in adolescent girls using either depot medroxyprogesterone acetate or an oral contraceptive. J Pediatr Adolesc Gynecol 2004, 17:373.
19. Jeppsson S., Gershagen S., Johansson E.D.B., et al. Serum medroxyprogesterone (MPA), sex hormone binding globulin, gonadal steroids, gonadotrophins and prolactin in women during long-term use of depo-MPA as a contraceptive. Acta Endocrinol 1982, 99:339.
20. Clark M.K., Sowers M., Levy B.T., et al. Magnitude and variability of sequential estradiol and progesterone concentrations in women using depot medroxyprogesterone acetate for contraception. Fertil Steril 2001, 75:871.
21. Johnson C.C., Burkman R.T., Gold M.A., et al. Longitudinal study of depot medroxyprogesterone acetate (Depo-Provera) effects on bone health in adolescents: Study design, population characteristics and baseline bone mineral density. Contraception 2008, 77:239.
22. Holick M.F. Vitamin D deficiency. N Engl J Med 2007, 357:266.
23. Gordon C.M., DePeter K.C., Feldman H.A., et al. Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med 2004, 158:531.
24. Harkness L.S., Cromer B.A. Vitamin D deficiency in adolescent females. J Adolesc Health 2005, 37:75.
25. Lehtonen-Veromaa M.K., Mottonen T.T., Nuotio I.O., et al. Vitamin D and attainment of peak bone mass among peripubertal Finnish girls: A 3-year prospective study. Am J Clin Nutr 2002, 76:1446.
26. Viljakainen H.T., Natri A.M., Karkkainen M.M., et al. A positive dose-response effect of vitamin D supplementation on site-specific bone mineral augmentation in adolescent girls: A double-blinded randomized placebo-controlled 1-year intervention. J Bone Miner Res 2006, 21:836.
27. Bischoff-Ferrari H.A., Dietrich T., Orav E.J., et al. Positive association between 25 (OH) D levels and bone mineral density: A population-based study of younger and older adults. Am J Med 2004, 116:634.
28. Weaver C.M., Fleet J.C. Vitamin D requirements: current and future. Am J Clin Nutr 2004, 80:1735S.
29. Outila T.A., Karkkainen M.U., Lamberg-Allardt C.J. Vitamin D status affects serum parathyroid hormone concentrations during winter in female adolescents: Associations with forearm bone mineral density. Am J Clin Nutr 2001, 74:206.
30. Wagner C.L., Greer F.R. Section on Breastfeeding and Committee on Nutrition: Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics 2008, 122:1142.
31. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine: Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride 1997, National Academy Press, Washington, DC.
32. Nordin B.E.C. Calcium and osteoporosis. Nutrition 1997, 13:664.
33. O'Loughlin P.D., Morris H.A. Oestrogen deficiency impairs intestinal calcium absorption in the rat. J Physiol 1998, 511:313.
34. Liel Y., Shany S., Smirnoff P., et al. Estrogen increases 1,25-dihydroxyvitamin D receptors expression and bioresponse in the rat duodenal mucosa. Endocrinology 1999, 140:280.
35. Duque G., El Abdaimi K., Macoritto M., et al. Estrogens (E2) regulate expression and response of 1,25-dihydroxyvitamin D3 receptors in bone cells: Changes with aging and hormone deprivation. Biochem Biophys Res Commun 2002, 299:446.
36. Merki-Feld G.S., Neff M., Keller P.J. A 2-year prospective study on the effects of depot medroxyprogesterone acetate on bone mass-response to estrogen and calcium therapy in individual users. Contraception 2003, 67:79.